Category - Markets

Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its...

H.C. Wainwright initiated coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and $20 price target. The stock closed at $16.10 on July 24. Concert’s deuteration technology is a de-risked platform for...

Leerink initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “market perform” rating and a $24 price target. The stock closed at $22.75 on July 21. Analyst Geoffrey Porges writes that his rating and valuation...

Leerink launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with an “outperform” rating and $23 one-year price target, representing an approximate $500-million valuation. The stock closed at $14.05 on July 21...

RBC Capital Markets upgraded CRH Medical (TSX:CRH; NYSE MKT:CRHM) to “outperform” from “sector perform” but lowered its price target to $6 (Canadian) from $8.50. The stock closed at $4.07 on July 20. Analyst Doug Miehm...

H.C. Wainwright launched coverage of Agile Therapeutics (NASDAQ:AGRX) with a “buy” rating and $10 price target, saying the company is significantly undervalued assuming its Twirla combination hormonal contraceptive...

BTIG initiated coverage of Eiger BioPharmaceuticals (NASDAQ:EIGR) with a “buy” rating and $32 price target. The stock closed at $7.45 on July 13. Eiger has four significant assets in Phase 2 clinical testing for four...

H.C. Wainwright downgraded Inotek Pharmaceuticals (NASDAQ:ITEK) to “neutral” from “buy” and slashed its price target to $2 from $7 after a failed Phase 2 trial. The stock closed at 96 cents on July 11. A fixed-dose...

Stifel upgraded Durect (NASDAQ:DRRX) to “buy” from “hold” and raised its price target to $3 from $1.25 and also transitioned coverage to Adam Walsh from Annabel Samimy. The stock closed at $1.59 on July 11. Mr. Walsh...

H.C. Wainwright initiated coverage of Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a “buy” rating and $15 price target. The stock closed at $6.88 on July 10. Analyst Ed Arce writes that he expects a positive readout...